- Home
- DX vs ATAI Comparison
DX vs ATAI Comparison
Compare DX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DX | ATAI |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DX | ATAI |
|---|---|---|
| Price | $13.03 | $7.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.75 | ★ $15.88 |
| AVG Volume (30 Days) | 5.2M | ★ 8.6M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | ★ 65.77 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $11.83 | $3.27 |
| 52 Week High | $14.93 | $7.45 |
Technical Indicators
Market Signals| Indicator | DX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 75.74 |
| Support Level | $12.93 | $3.89 |
| Resistance Level | $13.24 | N/A |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 49.37 | 87.93 |
Price Performance
Historical ComparisonAbout DX Dynex Capital Inc.
Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.